Health Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Piazza Martiri Della Libertà 33, 56127, Pisa, Italy.
Cardiology and Cardiovascular Medicine Division, Fondazione Monasterio, Via G. Moruzzi 1, 56124, Pisa, Italy.
Heart Fail Rev. 2024 Nov;29(6):1201-1215. doi: 10.1007/s10741-024-10430-w. Epub 2024 Aug 9.
Increased sympathetic and reduced parasympathetic nerve activity is associated with disease progression and poor outcomes in patients with chronic heart failure. The demonstration that markers of autonomic imbalance and vagal dysfunction, such as reduced heart rate variability and baroreflex sensitivity, hold prognostic value in patients with chronic heart failure despite modern therapies encourages the research for neuromodulation strategies targeting the vagus nerve. However, the approaches tested so far have yielded inconclusive results. This review aims to summarize the current knowledge about the role of the parasympathetic nervous system in chronic heart failure, describing the pathophysiological background, the methods of assessment, and the rationale, limits, and future perspectives of parasympathetic stimulation either by drugs or bioelectronic devices.
交感神经活性增加和副交感神经活性降低与慢性心力衰竭患者的疾病进展和不良预后相关。尽管采用了现代治疗方法,但自主神经失衡和迷走神经功能障碍的标志物(如心率变异性和压力反射敏感性降低)在慢性心力衰竭患者中具有预后价值,这一发现促使人们研究针对迷走神经的神经调节策略。然而,迄今为止测试的方法并未得出明确的结果。本综述旨在总结目前关于副交感神经系统在慢性心力衰竭中的作用的知识,描述其病理生理学背景、评估方法以及药物或生物电子设备进行副交感神经刺激的原理、局限性和未来展望。
Heart Fail Rev. 2024-11
J Cardiovasc Transl Res. 2014-2-6
Curr Cardiol Rep. 2015-11
Heart Fail Clin. 2015-4
J Cardiol. 2012-2-16
Trends Cardiovasc Med. 2024-7